What does "therapeutics company" mean?

A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.

Which European countries lead in therapeutics?

Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.

How are therapeutics companies verified in this directory?

Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.

Can I compare two therapeutic developers side by side?

Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.

16 therapeutics companies in Switzerland

EPFL Innovation Park (Lausanne) Phase 3 clinical-stage autoinflammatory disease biotech developing Tadekinig alfa for IL-18 driven rare diseases, with a 650 million USD partnership with Nippon Shinyaku for US commercialization.

Lead: Djordje FilipovicChief Executive Officer
Scale: Phase 3 clinical biologics development

Epalinges-based NYSE-listed (ADCT) antibody-drug conjugate company, with FDA-approved Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma and a broader oncology ADC pipeline.

Lead: Ameet MallikChief Executive Officer
Scale: Commercial ADC oncology

Geneva cell and gene therapy biotech with miRNA-mediated gene silencing technology, developing off-the-shelf cellular immunotherapies led by miCAR7, an allogeneic anti-CD7 CAR-T product.

Lead: Marco AlessandriniChief Executive Officer
Scale: Preclinical cell-therapy development

Basel shielded-cell therapy biotech developing paired cell-shielding and immunotherapy portfolios for hematologic disorders, with 46 million CHF Series A financing from Versant Ventures' Ridgeline Discovery Engine.

Lead: Thomas FuchsChief Executive Officer
Scale: Preclinical cell-therapy development

Allschwil (Basel area) ETH Zurich spin-off developing off-the-shelf soluble T-cell receptor (TCR) therapeutics for solid tumours, with 15.5 million CHF seed financing and BaseLaunch backing.

Lead: Lars NiebaChief Executive Officer
Scale: Preclinical TCR therapeutic development

Lugano- and Bethesda-based clinical-stage biotech developing allosteric small-molecule therapies for rare and neurodegenerative diseases, Nasdaq-listed under GANX.

Lead: Gene MackPresident and Chief Executive Officer
Scale: Clinical-stage small-molecule development

Bern-headquartered nanomedicine biotech with a liposomal drug-delivery platform (Talineuren, Talidox) and production processes developed at the Marly Innovation Center, running Swiss clinical trials in breast cancer and Parkinson's disease.

Lead: Peter HalbherrChairman and General Manager
Scale: Clinical-stage liposomal therapeutics

Schlieren antibody-discovery biotech built on the proprietary DROPZYLLA microfluidic single-cell platform, with a Phase II lead program (potravitug) for BK polyomavirus in kidney transplantation and a 2026 CSL collaboration worth up to 328 million USD.

Lead: Erik van den BergChief Executive Officer
Scale: Late-stage clinical antibody development

Basel clinical-stage CNS biotech developing therapies for orphan neurological disorders driven by imbalanced neuronal networks, built on ex-Roche assets and backed by Sofinnova Partners with a 103 million EUR financing.

Lead: Ilise LombardoChief Executive Officer
Scale: Clinical-stage CNS therapeutics

Basel immunotherapy company engineering cytokine-based treatments for cancer and immune disorders from a Swiss biotech platform.

Lead: Dario NeriChief Executive Officer
Scale: Clinical-stage immunotherapy platform

Basel biotech company developing Claudin-1 targeted therapeutics across fibrosis and oncology from a clinical-stage Swiss platform.

Lead: Mark PruzanskiChief Executive Officer
Scale: Clinical-stage therapeutics platform

Allschwil discovery and development anchor focused on small-molecule therapeutics across neuroscience, cardiovascular, and metabolic disease platforms.

Lead: Martine ClozelChief Executive Officer
Scale: Swiss discovery and development headquarters

Basel anti-infectives and oncology-development anchor operating a highly specialized therapeutics portfolio with partnered commercial reach.

Lead: David VeitchChief Executive Officer
Scale: Clinical and partnered specialty development

Lausanne oncology and specialty-therapeutics development anchor operating with a clinical-development and partnering model.

Lead: Frédéric LévyChief Executive Officer, Debiopharm International
Scale: Clinical and partnered development

Basel therapeutic and industrial-control anchor spanning advanced medicines, global supply governance, and large-scale pharmaceutical operations.

Lead: Vas NarasimhanChief Executive Officer
Scale: Global pharmaceutical operations

Basel therapeutics and diagnostics anchor with a global industrial network spanning pharma, biologics, and advanced diagnostics.

Lead: Thomas SchineckerChief Executive Officer
Scale: Global therapeutics and diagnostics operations

Therapeutics companies in Switzerland

Where does therapeutics cluster in Switzerland?

Which standards are already visible?

Therapeutics profiles in Switzerland

AB2 Bio Ltd.

ADC Therapeutics SA

Antion Biosciences SA

Cimeio Therapeutics AG

Engimmune Therapeutics

Gain Therapeutics SA

InnoMedica Holding AG

Memo Therapeutics AG

Noema Pharma AG

Anaveon

Alentis Therapeutics

Idorsia

Basilea

Debiopharm

Novartis

Roche

Read deeper on this category

EU Biotech Regulation 2026: What Changed and Who It Affects

Frequently asked questions on this category

Compare companies or open the wider market.